Why I'm Getting Asked About Peptides Every Day in My Portland Sports Medicine Clinic

Over the past year — and especially the past few months — I’ve noticed something interesting in my Portland sports medicine clinic.
I am now asked about peptides multiple times per day: 

CJC1295. Ipamorelin. Sermorelin. BPC157. Tesamorelin.

Patients are hearing about them on social media, podcasts, longevity influencers, fitness channels, and increasingly in mainstream political conversations. With national attention on health reform and regulatory discussions, peptides are suddenly everywhere. So let’s talk about what they are — and what they aren’t.

Why Peptides Are Trending

Peptides are small chains of amino acids that act as signaling molecules in the body. Some stimulate growth hormone. Others are proposed to influence healing pathways or metabolism. Online, they are often marketed as:

 Faster injury healing
 Muscle growth
 Fat loss
 Recovery optimization
 “Regenerative” shortcuts

It’s easy to understand the appeal. Who wouldn’t want a quicker return from a tendon injury? A way to accelerate recovery? A performance edge? But here’s where we need to separate enthusiasm from evidence.

The Evidence Problem

In my clinic, I treat tendon injuries, ligament sprains, cartilage problems, arthritis, and overuse conditions every day. At this time:

 There are no highquality human clinical trials showing that CJC1295, Ipamorelin,
Sermorelin, or BPC157 improve tendon, ligament, or cartilage healing.

 Tesamorelin is FDA approved — but only for a specific HIV related fat redistribution condition, not for injury recovery.

 Most of the “healing” data circulating online comes from animal studies or laboratory models.

Animal data is interesting. It is not the same as human outcome evidence.
That distinction matters.

What Patients Are Really Asking

When someone asks me about peptides, what they’re really saying is:
“I want to heal faster.”
“I want the best technology available.”
“I don’t want to miss my season.”
“I’m tired of being injured.”

Those are reasonable goals, and as a frequently injured aging athlete they are my goals as well. But my job is to recommend treatments that have been tested in real people, with measurable outcomes, reproducibility, and safety data.
That’s the difference between biological plausibility and clinical validation.

Safety and Regulation

Another issue is regulation. Many of the peptides being marketed for injury recovery are:

 Not FDAapproved
 Compounded without standardized dosing oversight
 Purchased online
 Not subject to the same manufacturing controls as approved medications

Competitive athletes should also know that many growthhormone–related compounds are WADAprohibited. Growth hormone–modulating agents can affect blood sugar, fluid retention, and potentially stimulate unintended tissue growth. Longterm safety data in healthy athletic populations is limited or nonexistent.
That doesn’t mean they are inherently dangerous — but it does mean we don’t fully understand their riskbenefit profile in musculoskeletal injury.

What I Offer Instead

In my practice, we focus on treatments supported by human clinical research, including:

 Ultrasoundguided precision injections
 Plateletrich plasma (PRP) for select conditions
 Shockwave therapy
 Structured tendon loading protocols
 Biomechanicsbased rehabilitation

These aren’t shortcuts. They are evidenceguided interventions designed to optimize tissue healing and longterm function.
They require discipline and patience. But they work — and we have real data to support them.

Why You’re Hearing So Much About Peptides

Social media rewards novelty. Algorithms amplify bold claims. Influencers promote what feels cuttingedge.
When peptides receive attention from highlevel policy discussions or government figures, it further legitimizes public curiosity. But curiosity and clinical proof are not the same thing. Medicine moves deliberately for a reason.

My Position

If strong human clinical trials emerge showing that a peptide meaningfully improves tendon or ligament healing — I will absolutely evaluate it. I’m not antiinnovation. I’m proevidence.

Until then, I will continue recommending treatments that have:

 Human outcome data
 Clear dosing standards
 Defined safety profiles
 Transparent regulatory oversight

In sports medicine, the goal is not just faster healing. It’s durable healing.

And that requires more than a trending molecule.

If you’re curious about a specific peptide you’ve heard about, bring it up at your visit. I’m always happy to have the conversation — and to help you separate marketing from medicine.

Author

David Westerdahl MD FAAFP RMSK Sports Medicine Physician and owner Sports Health Northwest, Inc.